What is cagrilintide?
Cagrilintide (development code AM833) is a long-acting synthetic analog of amylin — a small peptide hormone that the pancreas releases together with insulin after a meal. Native amylin is one of the body’s natural “stop eating” signals, but it breaks down within minutes, which makes the hormone itself useless as a once-weekly research tool. Cagrilintide is the engineered, stabilised version: a fatty-acid chain attached to the peptide lets it bind reversibly to albumin in the blood, creating a slow-release depot that stretches its half-life from minutes to about a week.
Where the GLP-1 peptides everyone now knows (semaglutide, and the GLP-1 arm of retatrutide) act on the incretin system, cagrilintide works on a completely separate axis — the amylin/calcitonin receptor family. That is the whole point of the molecule: it is a second, independent lever on appetite that can be pulled alongside a GLP-1 rather than instead of it.
How cagrilintide works: the amylin axis
Cagrilintide is best described as a dual amylin/calcitonin receptor co-agonist. It engages the calcitonin receptor (CTR) together with the RAMP-modified amylin receptor complexes (AMY1 and AMY3 are the main functional targets) that cluster in the area postrema and dorsal vagal complex of the brainstem — the region that reads circulating satiety signals. Three downstream effects are consistently reported in the preclinical and clinical literature:
| Effect | Mechanism | Net result |
|---|---|---|
| Appetite reduction | Central amylin-receptor signalling in the brainstem satiety centres | Lower food intake |
| Slowed gastric emptying | Delays stomach emptying by roughly 40–50% vs baseline in studies | Prolonged fullness after a meal |
| Glucagon suppression | Reduces postprandial glucagon secretion | Steadier post-meal glucose handling |
Preclinical work confirmed that the weight effect depends specifically on the AMY1 and AMY3 receptors in the hindbrain — i.e. central amylin signalling is the mechanistic backbone, not a peripheral side effect. Because this pathway is orthogonal to GLP-1, combining the two produces additive, not redundant, appetite suppression.
What the cagrilintide research shows
The clinical record splits into two chapters: cagrilintide on its own, and cagrilintide combined with semaglutide.
- Monotherapy (Phase 2, Lancet 2021). Once-weekly cagrilintide alone produced roughly 10.8% mean weight loss at 26 weeks in adults with obesity — a meaningful signal for a single amylin analog.
- CagriSema (Phase 3, REDEFINE 1, NEJM 2025). The fixed-dose combination of cagrilintide + semaglutide reached around 22.7% mean weight loss, with about 60% of participants losing ≥20% and roughly 23% losing ≥30% of bodyweight.
- The synergy is real. In the same program, semaglutide alone reached ~16.1% and cagrilintide alone ~11.8% — so the combination clearly exceeds either single axis, which is the scientific case for stacking amylin with a GLP-1.
Pharmacokinetics: why once-weekly
Cagrilintide reaches peak plasma concentration roughly 24–72 hours after a subcutaneous dose and has a reported half-life of about 7 days (≈159–195 hours). The albumin-binding fatty-acid chain is what slows renal clearance and stretches elimination, giving the long, flat exposure curve that makes once-weekly dosing feasible. This is the same half-life-engineering principle used across the modern metabolic peptides, including retatrutide’s ~6-day half-life.
Where cagrilintide sits in the next-gen landscape
The metabolic-peptide frontier is no longer a single race. Two parallel strategies are maturing at once: multi-agonism on the incretin axis (dual and triple GLP-1/GIP/glucagon agonists such as retatrutide) and amylin co-agonism (cagrilintide and the emerging amylin class). For the fuller multi-receptor picture, our quintuple-agonist guide maps where the receptor-stacking field is heading.
For researchers, the practical relevance is that the same handling and reconstitution workflow applies across all of these lyophilized peptides — see the reconstitution guide for the concentration math, and the complete research peptides guide for purity and storage standards.
Sourcing next-gen peptides: what to check
Newer compounds attract the highest density of low-quality material, because demand runs ahead of supply. The verification checklist does not change:
- Purity ≥ 99% by HPLC on a recent batch Certificate of Analysis from a named laboratory such as Janoshik.
- Identity confirmed by mass spectrometry matching the expected mass on the COA.
- White, intact lyophilizate in a vial sealed under vacuum or inert gas, shipped light-protected.
- A batch number on the COA that matches the vial — a generic certificate that never changes is a red flag.